{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:26:26Z","timestamp":1787905586448,"version":"build-2784847793"},"reference-count":132,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Botulinum neurotoxin (BoNT) is produced by the anaerobic, Gram-positive bacterium Clostridium botulinum. As one of the most poisonous toxins known and a potential bioterrosism agent, BoNT is characterized by a complex mode of action comprising: internalization, translocation and proteolytic cleavage of a substrate, which inhibits synaptic exocytotic transmitter release at neuro-muscular nerve endings leading to peripheral neuroparalysis of the skeletal and autonomic nervous systems. There are seven major serologically distinct toxinotypes (A\u2013G) of BoNT which act on different substrates. Human botulism is generally caused by BoNT\/A, B and E. Due to its extreme lethality and potential use as biological weapon, botulism remains a global public health concern. Vaccination against BoNT, although an effective strategy, remains undesirable due to the growing expectation around therapeutic use of BoNTs in various pathological conditions. This review focuses on the current approaches for botulism control by immunotherapy, highlighting the future challenges while the molecular underpinnings among subtypes variants and BoNT sequences found in non-clostridial species remain to be elucidated.<\/jats:p>","DOI":"10.3390\/toxins11090528","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T10:56:06Z","timestamp":1568285766000},"page":"528","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Antibodies and Vaccines against Botulinum Toxins: Available Measures and Novel Approaches"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0661-695X","authenticated-orcid":false,"given":"Christine","family":"Rasetti-Escargueil","sequence":"first","affiliation":[{"name":"Institut Pasteur, D\u00e9partement de Microbiologie, Unit\u00e9 des Toxines Bact\u00e9riennes, 25 Rue du Docteur Roux, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9305-8989","authenticated-orcid":false,"given":"Michel R.","family":"Popoff","sequence":"additional","affiliation":[{"name":"Institut Pasteur, D\u00e9partement de Microbiologie, Unit\u00e9 des Toxines Bact\u00e9riennes, 25 Rue du Docteur Roux, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Peck, M.W., Smith, T.J., Anniballi, F., Austin, J.W., Bano, L., Bradshaw, M., Cuervo, P., Cheng, L.W., Derman, Y., and Dorner, B.G. (2017). Historical perspectives and guidelines for botulinum neurotoxin subtype nomenclature. Toxins (Basel), 9.","DOI":"10.3390\/toxins9010038"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1086\/444507","article-title":"Botulism","volume":"41","author":"Sobel","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","unstructured":"Rasetti-Escargueil, C., and Surman-Lee, S. (2012). Botulism symptoms, incubation period and complications, diagnosis and management. Clostridium Botulinum: A Spore Forming Organism and a Challenge to Food Safety, Nova Science Publishers. Advances in Food Safety and Food Microbiology."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/00480169.1982.34902","article-title":"The occurrence of clostridium botulinum at aquatic sites in and around auckland and other urban areas of the North Island","volume":"30","author":"Gill","year":"1982","journal-title":"N. Z. Vet. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/mr.46.1.86-94.1982","article-title":"Bacterial toxins: A table of lethal amounts","volume":"46","author":"Gill","year":"1982","journal-title":"Microbiol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1074\/jbc.M707917200","article-title":"Molecular architecture of botulinum neurotoxin e revealed by single particle electron microscopy","volume":"283","author":"Fischer","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"Botulinum toxin as a biological weapon: Medical and public health management","volume":"285","author":"Arnon","year":"2001","journal-title":"JAMA"},{"key":"ref_8","unstructured":"Bozheyeva, G., Kunakbayev, Y., and Yeleukenov, D. (1999). Former Soviet Biological Weapons Facilities in Kazakhstan: Past, Present, and Future, Monterey Institute of International Studies."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9984","DOI":"10.1073\/pnas.0408526102","article-title":"Analyzing a bioterror attack on the food supply: The case of botulinum toxin in milk","volume":"102","author":"Wein","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"20034","DOI":"10.2807\/ese.16.49.20034-en","article-title":"Two cases of food-borne botulism in Finland caused by conserved olives, october 2011","volume":"16","author":"Jalava","year":"2011","journal-title":"Eurosurveillance"},{"key":"ref_11","first-page":"1489","article-title":"In vitro characterization of botulinum toxin types A, C and D action on human tissues: Combined electrophysiologic, pharmacologic and molecular biologic approaches","volume":"280","author":"Coffield","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1093\/cid\/cix818","article-title":"Type F infant botulism: Investigation of recent clusters and overview of this exceedingly rare disease","volume":"66","author":"Halpin","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/infdis\/jit449","article-title":"A novel strain of clostridium botulinum that produces type b and type h botulinum toxins","volume":"209","author":"Barash","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/infdis\/jiv327","article-title":"A novel botulinum neurotoxin, previously reported as serotype h, has a hybrid-like structure with regions of similarity to the structures of serotypes a and f and is neutralized with serotype a antitoxin","volume":"213","author":"Maslanka","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/infdis\/jiu211","article-title":"Validity of botulinum neurotoxin serotype h","volume":"210","author":"Johnson","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.febslet.2014.12.018","article-title":"Botulinum neurotoxin homologs in non-clostridium species","volume":"589","author":"Mansfield","year":"2015","journal-title":"FEBS Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14130","DOI":"10.1038\/ncomms14130","article-title":"Identification and characterization of a novel botulinum neurotoxin","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"30257","DOI":"10.1038\/srep30257","article-title":"The first non clostridial botulinum-like toxin cleaves vamp within the juxtamembrane domain","volume":"6","author":"Zornetta","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/1873-3468.13446","article-title":"Crystal structure of the catalytic domain of the weissella oryzae botulinum-like toxin","volume":"593","author":"Kosenina","year":"2019","journal-title":"FEBS Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/1873-3468.12969","article-title":"Identification of a novel botulinum neurotoxin gene cluster in enterococcus","volume":"592","author":"Brunt","year":"2018","journal-title":"FEBS Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/2338","article-title":"Crystal structure of botulinum neurotoxin type a and implications for toxicity","volume":"5","author":"Lacy","year":"1998","journal-title":"Nat. Struct. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jmb.2008.12.027","article-title":"Domain organization in clostridium botulinum neurotoxin type e is unique: Its implication in faster translocation","volume":"386","author":"Kumaran","year":"2009","journal-title":"J. Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1017\/S0033583500003292","article-title":"Structure and function of tetanus and botulinum neurotoxins","volume":"28","author":"Montecucco","year":"1995","journal-title":"Q. Rev. Biophys"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.biochem.051908.125345","article-title":"Botulinum neurotoxin: A marvel of protein design","volume":"79","author":"Montal","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.embor.7400796","article-title":"Entering neurons: Botulinum toxins and synaptic vesicle recycling","volume":"7","author":"Verderio","year":"2006","journal-title":"EMBO Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0928-4257(96)80550-X","article-title":"The metallo-proteinase activity of tetanus and botulism neurotoxins","volume":"89","author":"Rossetto","year":"1995","journal-title":"J. Physiol. Paris"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: Biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharm. Rev."},{"key":"ref_28","first-page":"355","article-title":"The ha proteins of botulinum toxin disrupt intestinal epithelial intercellular junctions to increase toxin absorption","volume":"10","author":"Matsumura","year":"2008","journal-title":"Cell. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1083\/jcb.200910119","article-title":"Botulinum hemagglutinin disrupts the intercellular epithelial barrier by directly binding e-cadherin","volume":"189","author":"Sugawara","year":"2010","journal-title":"J. Cell Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1038\/ncomms7255","article-title":"Botulinum toxin a complex exploits intestinal m cells to enter the host and exert neurotoxicity","volume":"6","author":"Matsumura","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/cmi.12502","article-title":"Translocation and dissemination to target neurons of botulinum neurotoxin type b in the mouse intestinal wall","volume":"18","author":"Connan","year":"2016","journal-title":"Cell. Microbiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/17460441.2017.1303476","article-title":"Challenges in searching for therapeutics against botulinum neurotoxins","volume":"12","author":"Pirazzini","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.vaccine.2018.02.042","article-title":"Safety and immunogenicity of investigational recombinant botulinum vaccine, rbv a\/b, in volunteers with pre-existing botulinum toxoid immunity","volume":"36","author":"Khouri","year":"2018","journal-title":"Vaccine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1056\/NEJMoa051926","article-title":"Human botulism immune globulin for the treatment of infant botulism","volume":"354","author":"Arnon","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1093\/cid\/cir550","article-title":"Initial recovery and rebound of type f intestinal colonization botulism after administration of investigational heptavalent botulinum antitoxin","volume":"53","author":"Fagan","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4161\/hv.9420","article-title":"Botulinum neurotoxin vaccines: Past history and recent developments","volume":"5","author":"Rusnak","year":"2009","journal-title":"Hum. Vaccines"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4049\/jimmunol.90.5.697","article-title":"Studies on immunity to toxins of clostridium botulinum. Ix. Immunologic response of man to purified pentavalent abcde botulinum toxiod","volume":"90","author":"Fiock","year":"1963","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0300-9084(00)01173-1","article-title":"Development of vaccines for prevention of botulism","volume":"82","author":"Byrne","year":"2000","journal-title":"Biochimie"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1128\/jcm.27.8.1906-1908.1989","article-title":"Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (abcde) toxoid","volume":"27","author":"Siegel","year":"1989","journal-title":"J. Clin. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1128\/CVI.00117-08","article-title":"Characterization of new formalin-detoxified botulinum neurotoxin toxoids","volume":"15","author":"Keller","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.biologicals.2012.03.004","article-title":"New equine antitoxins to botulinum neurotoxins serotypes a and b","volume":"40","author":"Li","year":"2012","journal-title":"Biologicals"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.toxicon.2015.11.010","article-title":"Retrospective survey to evaluate the safety and efficacy of japanese botulinum antitoxin therapy in japan","volume":"110","author":"Mottate","year":"2016","journal-title":"Toxicon"},{"key":"ref_43","unstructured":"CDC (2010). Investigational heptavalent botulinum antitoxin (hbat) to replace licensed botulinum antitoxin ab and investigational botulinum antitoxin E. Mmwr. Morb. Mortal. Wkly. Rep., 59, 299."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/archdischild-2018-315498","article-title":"Question 1: In infant botulism, is equine-derived botulinum antitoxin (eqba) an effective alternative therapy to human-derived botulinum immune globulin (big)?","volume":"103","author":"Moneim","year":"2018","journal-title":"Arch. Dis. Child."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1128\/IAI.73.9.5450-5457.2005","article-title":"Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization","volume":"73","author":"Smith","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Rasetti-Escargueil, C., Avril, A., Miethe, S., Mazuet, C., Derman, Y., Selby, K., Thullier, P., Pelat, T., Urbain, R., and Fontayne, A. (2017). The european antibotabe framework program and its update: Development of innovative botulinum antibodies. Toxins (Basel), 9.","DOI":"10.3390\/toxins9100309"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/15701638113109990030","article-title":"Isolation of antibodies from non-human primates for clinical use","volume":"11","author":"Avril","year":"2014","journal-title":"Curr. Drug Discov. Technol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4161\/mabs.1.4.8635","article-title":"Non-human primate immune libraries combined with germline humanization: An (almost) new, and powerful approach for the isolation of therapeutic antibodies","volume":"1","author":"Pelat","year":"2009","journal-title":"MAbs"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1128\/iai.65.5.1626-1630.1997","article-title":"Antibody mapping to domains of botulinum neurotoxin serotype a in the complexed and uncomplexed forms","volume":"65","author":"Chen","year":"1997","journal-title":"Infect. Immun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jmb.2006.09.084","article-title":"Fine and domain-level epitope mapping of botulinum neurotoxin type a neutralizing antibodies by yeast surface display","volume":"365","author":"Levy","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1128\/IAI.69.10.6511-6514.2001","article-title":"Epitope mapping of neutralizing botulinum neurotoxin a antibodies by phage display","volume":"69","author":"Mullaney","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1023\/B:JOPC.0000016257.91979.06","article-title":"Mapping of the antibody-binding regions on the hn-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the h-chain of botulinum neurotoxin A","volume":"23","author":"Atassi","year":"2004","journal-title":"Protein J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.molimm.2005.01.016","article-title":"Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A","volume":"42","author":"Atassi","year":"2005","journal-title":"Mol. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/S0264-410X(96)00094-1","article-title":"Mapping of protective and cross-reactive domains of the type a neurotoxin of clostridium botulinum","volume":"14","author":"Dertzbaugh","year":"1996","journal-title":"Vaccine"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Espinoza, Y., Wong, D., Ahene, A., Der, K., Martinez, Z., Pham, J., Cobb, R.R., Farr-Jones, S., Marks, J.D., and Tomic, M.T. (2019). Pharmacokinetics of human recombinant anti-botulinum toxin antibodies in rats. Toxins (Basel), 11.","DOI":"10.3390\/toxins11060345"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1128\/IAI.01084-09","article-title":"Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents","volume":"78","author":"Sepulveda","year":"2010","journal-title":"Infect. Immun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/hyb.2007.0549","article-title":"A natural human igm antibody that neutralizes botulinum neurotoxin in vivo","volume":"27","author":"Adekar","year":"2008","journal-title":"Hybridoma (Larchmt)"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jim.2008.01.015","article-title":"Hybridoma populations enriched for affinity-matured human iggs yield high-affinity antibodies specific for botulinum neurotoxins","volume":"333","author":"Adekar","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1016\/j.molimm.2008.06.031","article-title":"Molecular recognition of botulinum neurotoxin b heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment","volume":"45","author":"Atassi","year":"2008","journal-title":"Mol. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.imbio.2010.10.010","article-title":"Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin a: Antigenic structure of the entire toxin","volume":"216","author":"Dolimbek","year":"2011","journal-title":"Immunobiology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.toxicon.2015.06.003","article-title":"Molecular basis of immunogenicity to botulinum neurotoxins and uses of the defined antigenic regions","volume":"107","author":"Atassi","year":"2015","journal-title":"Toxicon"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1002\/mds.20023","article-title":"Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization","volume":"19","author":"Marks","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Mazuet, C., Dano, J., Popoff, M.R., Creminon, C., and Volland, H. (2010). Characterization of botulinum neurotoxin type a neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012416"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"11346","DOI":"10.1073\/pnas.172229899","article-title":"Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody","volume":"99","author":"Nowakowski","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.3390\/toxins7093405","article-title":"Monoclonal antibodies that inhibit the proteolytic activity of botulinum neurotoxin serotype\/b","volume":"7","author":"Fan","year":"2015","journal-title":"Toxins (Basel)"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Fan, Y., Garcia-Rodriguez, C., Lou, J., Wen, W., Conrad, F., Zhai, W., Smith, T.J., Smith, L.A., and Marks, J.D. (2017). A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype f subtypes. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174187"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Fan, Y., Geren, I.N., Dong, J., Lou, J., Wen, W., Conrad, F., Smith, T.J., Smith, L.A., Ho, M., and Pires-Alves, M. (2015). Monoclonal antibodies targeting the alpha-exosite of botulinum neurotoxin serotype\/a inhibit catalytic activity. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0135306"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/protein\/gzq111","article-title":"Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin","volume":"24","author":"Geren","year":"2011","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Garcia-Rodriguez, C., Razai, A., Geren, I.N., Lou, J., Conrad, F., Wen, W.H., Farr-Jones, S., Smith, T.J., Brown, J.L., and Skerry, J.C. (2018). A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype e subtypes. Toxins (Basel), 10.","DOI":"10.3390\/toxins10030105"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Diamant, E., Lachmi, B.E., Keren, A., Barnea, A., Marcus, H., Cohen, S., David, A.B., and Zichel, R. (2014). Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087089"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1134\/S1068162011030022","article-title":"Monoclonal antibodies to type a, b, e and f botulinum neurotoxins","volume":"37","author":"Abbasova","year":"2011","journal-title":"Russ. J. Bioorganic Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3390\/toxins4121565","article-title":"Sheep monoclonal antibodies prevent systemic effects of botulinum neurotoxin a1","volume":"4","author":"Mukherjee","year":"2012","journal-title":"Toxins (Basel)"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kalb, S.R., Santana, W.I., Geren, I.N., Garcia-Rodriguez, C., Lou, J., Smith, T.J., Marks, J.D., Smith, L.A., Pirkle, J.L., and Barr, J.R. (2011). Extraction and inhibition of enzymatic activity of botulinum neurotoxins \/b1, \/b2, \/b3, \/b4, and \/b5 by a panel of monoclonal anti-bont\/b antibodies. BMC Biochem., 12.","DOI":"10.1186\/1471-2091-12-58"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Chen, C., Wang, S., Wang, H., Mao, X., Zhang, T., Ji, G., Shi, X., Xia, T., Lu, W., and Zhang, D. (2012). Potent neutralization of botulinum neurotoxin\/b by synergistic action of antibodies recognizing protein and ganglioside receptor binding domain. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0043845"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Tomic, M.T., Espinoza, Y., Martinez, Z., Pham, K., Cobb, R.R., Snow, D.M., Earnhart, C.G., Pals, T., Syar, E.S., and Niemuth, N. (2019). Monoclonal antibody combinations prevent serotype a and serotype b inhalational botulism in a guinea pig model. Toxins (Basel), 11.","DOI":"10.3390\/toxins11040208"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1348-0421.2012.00503.x","article-title":"Characterization of neutralizing mouse-human chimeric and shuffling antibodies against botulinum neurotoxin A","volume":"56","author":"Mukamoto","year":"2012","journal-title":"Microbiol. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"46","DOI":"10.7883\/yoken.66.46","article-title":"Production of a neutralizing mouse-human chimeric antibody against botulinum neurotoxin serotype E","volume":"66","author":"Mukamoto","year":"2013","journal-title":"Jpn. J. Infect. Dis"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Prigent, J., Mazuet, C., Boquet, D., Lamourette, P., Volland, H., Popoff, M.R., Creminon, C., and Simon, S. (2010). Production and characterisation of a neutralising chimeric antibody against botulinum neurotoxin A. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013245"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.vaccine.2009.02.051","article-title":"Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin","volume":"27","author":"Takahashi","year":"2009","journal-title":"Vaccine"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1128\/IAI.00405-09","article-title":"Antibody protection against botulinum neurotoxin intoxication in mice","volume":"77","author":"Cheng","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.molimm.2013.09.005","article-title":"Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor","volume":"57","author":"Sharma","year":"2014","journal-title":"Mol. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Al-Saleem, F.H., Sharma, R., Puligedda, R.D., Elias, M., Kattala, C.D., Simon, P.M., Simpson, L.L., and Dessain, S.K. (2017). Rbc adherence of immune complexes containing botulinum toxin improves neutralization and macrophage uptake. Toxins (Basel), 9.","DOI":"10.3390\/toxins9050173"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Adekar, S.P., Segan, A.T., Chen, C., Bermudez, R., Elias, M.D., Selling, B.H., Kapadnis, B.P., Simpson, L.L., Simon, P.M., and Dessain, S.K. (2011). Enhanced neutralization potency of botulinum neurotoxin antibodies using a red blood cell-targeting fusion protein. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017491"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Adekar, S.P., Takahashi, T., Jones, R.M., Al-Saleem, F.H., Ancharski, D.M., Root, M.J., Kapadnis, B.P., Simpson, L.L., and Dessain, S.K. (2008). Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003023"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1124\/jpet.111.180653","article-title":"Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: A model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare","volume":"338","author":"Nasser","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Shoemaker (2018). Design options for mrna-encoded bont antitoxins employing camelid single-domain antibody (vhh) components. Toxicon, 156, S120.","DOI":"10.1016\/j.toxicon.2018.11.251"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"15776","DOI":"10.1038\/srep15776","article-title":"Antigenic sites on the hn domain of botulinum neurotoxin a stimulate protective antibody responses against active toxin","volume":"5","author":"Ayyar","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.febslet.2014.02.034","article-title":"Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A","volume":"588","author":"Strotmeier","year":"2014","journal-title":"FEBS Lett."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.febslet.2004.06.094","article-title":"Interaction between the two subdomains of the c-terminal part of the botulinum neurotoxin a is essential for the generation of protective antibodies","volume":"572","author":"Tavallaie","year":"2004","journal-title":"FEBS Lett."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/pbi.12244","article-title":"Algal chloroplast produced camelid vh h antitoxins are capable of neutralizing botulinum neurotoxin","volume":"13","author":"Barrera","year":"2015","journal-title":"Plant. Biotechnol. J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/bab.1226","article-title":"Camelid-derived heavy-chain nanobody against clostridium botulinum neurotoxin E in pichia pastoris","volume":"63","author":"Baghban","year":"2016","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.toxicon.2010.07.003","article-title":"Camelid single domain antibodies (vhhs) as neuronal cell intrabody binding agents and inhibitors of clostridium botulinum neurotoxin (bont) proteases","volume":"56","author":"Tremblay","year":"2010","journal-title":"Toxicon"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41467-017-00448-0","article-title":"Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin","volume":"8","author":"Huang","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1128\/IAI.01269-08","article-title":"Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer","volume":"77","author":"Trollet","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.4315\/0362-028X-72.5.1005","article-title":"Egg yolk antibodies for detection and neutralization of clostridium botulinum type A neurotoxin","volume":"72","author":"Trott","year":"2009","journal-title":"J. Food Prot."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.25192","article-title":"DNA electroporation in rabbits as a method for generation of high-titer neutralizing antisera: Examples of the botulinum toxins types A, B, and E","volume":"9","author":"Burgain","year":"2013","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_97","first-page":"219","article-title":"Phage libraries for generation of anti-botulinum scfv antibodies","volume":"145","author":"Amersdorfer","year":"2000","journal-title":"Methods Mol. Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1128\/iai.65.9.3743-3752.1997","article-title":"Molecular characterization of murine humoral immune response to botulinum neurotoxin type a binding domain as assessed by using phage antibody libraries","volume":"65","author":"Amersdorfer","year":"1997","journal-title":"Infect. Immun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/S0264-410X(01)00482-0","article-title":"Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries","volume":"20","author":"Amersdorfer","year":"2002","journal-title":"Vaccine"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1128\/AEM.67.7.3201-3207.2001","article-title":"Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the clostridium botulinum neurotoxin type A","volume":"67","author":"Wu","year":"2001","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.bmcl.2008.12.055","article-title":"Selection and characterization of a human monoclonal neutralizing antibody for clostridium botulinum neurotoxin serotype B","volume":"19","author":"Zhou","year":"2009","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1177\/1087057109343206","article-title":"Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library","volume":"14","author":"Yu","year":"2009","journal-title":"J. Biomol. Screen."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/protein\/gzq001","article-title":"Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating","volume":"23","author":"Lou","year":"2010","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12033-013-9669-1","article-title":"In vivo neutralization of botulinum neurotoxins serotype e with heavy-chain camelid antibodies (vhh)","volume":"55","author":"Bakherad","year":"2013","journal-title":"Mol. Biotechnol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/infdis\/jiv770","article-title":"Immunological characterization and neutralizing ability of monoclonal antibodies directed against botulinum neurotoxin type H","volume":"213","author":"Fan","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Pellett, S., Tepp, W.H., Bradshaw, M., Kalb, S.R., Dykes, J.K., Lin, G., Nawrocki, E.M., Pier, C.L., Barr, J.R., and Maslanka, S.E. (2016). Purification and characterization of botulinum neurotoxin fa from a genetically modified clostridium botulinum strain. mSphere, 1.","DOI":"10.1128\/mSphere.00100-15"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Li, M., Lee, D., Obi, C.R., Freeberg, J.K., Farr-Jones, S., and Tomic, M.T. (2018). An ambient temperature-stable antitoxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197011"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1128\/AAC.02830-14","article-title":"Safety and pharmacokinetics of xoma 3ab, a novel mixture of three monoclonal antibodies against botulinum toxin A","volume":"58","author":"Nayak","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"D33","DOI":"10.1016\/j.vaccine.2009.08.059","article-title":"Botulism and vaccines for its prevention","volume":"27","author":"Smith","year":"2009","journal-title":"Vaccine"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.parkreldis.2011.06.017","article-title":"New and emerging indications of botulinum toxin therapy","volume":"17","author":"Kaji","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Fonfria, E., Maignel, J., Lezmi, S., Martin, V., Splevins, A., Shubber, S., Kalinichev, M., Foster, K., Picaut, P., and Krupp, J. (2018). The expanding therapeutic utility of botulinum neurotoxins. Toxins (Basel), 10.","DOI":"10.3390\/toxins10050208"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.toxicon.2017.09.003","article-title":"An update on new and unique uses of botulinum toxin in movement disorders","volume":"147","author":"Jankovic","year":"2018","journal-title":"Toxicon"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.coph.2009.03.004","article-title":"Neuro-exocytosis: Botulinum toxins as inhibitory probes and versatile therapeutics","volume":"9","author":"Dolly","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.mib.2012.05.012","article-title":"Clinical applications of botulinum toxin","volume":"15","author":"Dressler","year":"2012","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00702-017-1762-3","article-title":"A brief history of neurological botulinum toxin therapy in germany","volume":"124","author":"Dressler","year":"2017","journal-title":"J. Neural Transm. (Vienna)"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/14764170903137121","article-title":"Differences in botulinum toxins: Time to end the confusion","volume":"11","author":"Brin","year":"2009","journal-title":"J. Cosmet. Laser Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpsychires.2012.01.027","article-title":"Facing depression with botulinum toxin: A randomized controlled trial","volume":"46","author":"Wollmer","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/NDT.S181820","article-title":"Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm","volume":"15","author":"Dong","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.vaccine.2017.12.064","article-title":"Enhancing toxin-based vaccines against botulism","volume":"36","author":"Przedpelski","year":"2018","journal-title":"Vaccine"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1016\/j.vaccine.2011.04.045","article-title":"Immunization of mice with the non-toxic hc50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge","volume":"29","author":"Mustafa","year":"2011","journal-title":"Vaccine"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1128\/CVI.00496-09","article-title":"Efficacy of a potential trivalent vaccine based on hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system","volume":"17","author":"Zichel","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.vaccine.2013.03.046","article-title":"Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based semliki forest virus replicon vectors","volume":"31","author":"Yu","year":"2013","journal-title":"Vaccine"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.4161\/hv.28937","article-title":"Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based semliki forest virus replicon vectors","volume":"10","author":"Yu","year":"2014","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"7313","DOI":"10.1016\/j.vaccine.2010.08.076","article-title":"Botulinum neurotoxin neutralizing activity of immune globulin (ig) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rbv a\/b)","volume":"28","author":"Shearer","year":"2010","journal-title":"Vaccine"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1080\/21645515.2015.1066051","article-title":"DNA vaccines targeting heavy chain c-terminal fragments of clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge","volume":"11","author":"Scott","year":"2015","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1634\/stemcells.2006-0616","article-title":"Baculoviral vector-mediated transient and stable transgene expression in human embryonic stem cells","volume":"25","author":"Zeng","year":"2007","journal-title":"Stem Cells"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1128\/IAI.00166-11","article-title":"Rapid immune responses to a botulinum neurotoxin hc subunit vaccine through in vivo targeting to antigen-presenting cells","volume":"79","author":"White","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/intimm\/dxr106","article-title":"Sublingual immunization with adenovirus f protein-based vaccines stimulates protective immunity against botulinum neurotoxin a intoxication","volume":"24","author":"Jun","year":"2012","journal-title":"Int. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"423","DOI":"10.7883\/yoken.JJID.2016.360","article-title":"Clinical study of new tetravalent (type A, B, E, and F) botulinum toxoid vaccine derived from m toxin in japan","volume":"70","author":"Torii","year":"2017","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Webb, R.P., Smith, T.J., Smith, L.A., Wright, P.M., Guernieri, R.L., Brown, J.L., and Skerry, J.C. (2017). Recombinant botulinum neurotoxin hc subunit (bont hc) and catalytically inactive clostridium botulinum holoproteins (cibont hps) as vaccine candidates for the prevention of botulism. Toxins (Basel), 9.","DOI":"10.3390\/toxins9090269"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/21645515.2017.1405201","article-title":"A mutated recombinant subunit vaccine protects mice and guinea pigs against botulinum type A intoxication","volume":"14","author":"Yu","year":"2018","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"452e","DOI":"10.1097\/PRS.0000000000004146","article-title":"Reply: Comparison of steroid and botulinum toxin type a monotherapy with combination therapy for treating human hypertrophic scars in an animal model","volume":"141","author":"Chen","year":"2018","journal-title":"Plast. Reconstr. Surg."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/11\/9\/528\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:19:23Z","timestamp":1760188763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/11\/9\/528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":132,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["toxins11090528"],"URL":"https:\/\/doi.org\/10.3390\/toxins11090528","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,12]]}}}